Astellas Pharma Inc (ALPMY) 15.4200 $ALPMY
Sanofi's Bid for Medivation Is Too Low
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 1:38PM CDT
Image source: Flickr user StockMonkeys.com. After waiting for weeks for a reply to its M&A offer, drug giant Sanofi has gone public with a $9.3 billion bid to acquire mid-cap cancer drugmaker Medivation . Sanofi's purchase price is...
MDVN: 58.89 (-0.08), JNJ: 116.46 (+0.28), GILD: 82.45 (+0.66), SNY: 40.29 (+0.50), NVS: 79.71 (+0.25)
J&J's Q1 Results Suggest More Upside for Medivation, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 7:01AM CDT
SOURCE: JOHNSON & JOHNSON Johnson & Johnson has reported its first-quarter financials, and the report shows that market share for its top selling prostate cancer drug Zytiga slipped slightly in the quarter. The loss of market share in...
MDVN: 58.89 (-0.08), JNJ: 116.46 (+0.28)
Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 10:50AM CDT
Medivation (MDVN) and Astellas (ALPMY) announced that the EMA's CHMP has issued a positive opinion in favor of the inclusion of new data in Xtandi's label.
MDVN: 58.89 (-0.08), AZN: 28.70 (+0.06), AMAG: 24.46 (+0.83)
Medivation Prostate Cancer Drug Xtandi under Pricing Attack
Arpita Dutt - Zacks Investment Research - Tue Mar 29, 9:30AM CDT
Americans are charged more for Medivation's (MDVN) prostate cancer drug, Xtandi, compared to countries like Sweden, Japan and Canada.
MDVN: 58.89 (-0.08), VRX: 21.64 (unch)
Technical Data Influencing the Market - Analyst Notes on CUBA Beverage, Arch Therapeutics, Wolseley and Astellas Pharma
ACCESSWIRE - Wed Mar 09, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CUBA Beverage Co. (OTC: CUBV), Arch Therapeutics Inc. (OTC: ARTH), Wolseley PLC (OTC: WOSYY) and Astellas Pharma Inc. (OTC: ALPMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
3 Reasons Medivation, Inc. Stock Could Rise
Cory Renauer, The Motley Fool - Motley Fool - Fri Mar 04, 2:39PM CST
Along with the rest of the healthcare industry, Medivation stock has had a rough year, even despite a 10% pop following recently-announced strong fourth-quarter earnings. The boost was especially welcome after the beating Medivation has received...
MDVN: 58.89 (-0.08), JNJ: 116.46 (+0.28)
Amgen Kyprolis' Label Expanded, Repatha Approved in Japan
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 3:30PM CST
The label for Amgen's (AMGN) Kyprolis has been expanded in the U.S. and accelerated approval has been converted to full approval; Repatha gains approval in Japan.
AMGN: 149.81 (+0.39), ANIK: 50.27 (+0.10), CELG: 99.23 (+2.37)
Where We Are Headed - Featured Research on Airbus Group, Astellas Pharma, Brambles and Detour Gold
ACCESSWIRE - Fri Jan 22, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Airbus Group SE (OTC: EADSY), Astellas Pharma Inc. (OTC: ALPMY), Brambles Ltd. (OTC: BXBLY) and Detour Gold Corp. (OTC: DRGDF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Ironwood Highlights Strategic Objectives, Provides Outlook
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 3:25PM CST
Ironwood Pharmaceuticals (IRWD) provided a comprehensive overview of its initiatives by highlighting three- and five-year operational and financial goals.
AGN: 228.55 (-3.00), IRWD: 12.64 (-0.04), AZN: 28.70 (+0.06)
Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:50PM CST
Vical's (VICL) antifungal candidate, VL-2397, was granted Orphan Drug designation for the treatment of patients with invasive aspergillosis.
VICL: 4.36 (+0.03), HZNP: 16.78 (+0.04), LGND: 113.83 (-0.16)
Ocata Therapeutics Almost Doubled in November -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Fri Dec 04, 3:03PM CST
What: Shares of eye-disease-focused Ocata Therapeutics posted a huge 88% gain during the month of November after the company accepted a buyout offer for a healthy premium, according to data from S&P Capital IQ . So what: Early in the...
OCAT: 8.47 (+0.01)
Ironwood/Astellas Report Positive Phase III Data on Linzess
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 3:55PM CST
Ironwood Pharmaceuticals (IRWD) and Astellas reported positive top-line phase III data on Linzess; Astellas will file for its approval in Japan in 2016.
AGN: 228.55 (-3.00), IRWD: 12.64 (-0.04), ACHN: 8.40 (-0.02)
Mallinckrodt (MNK) Sells Contrast Media & Delivery Systems
Zacks Equity Research - Zacks Investment Research - Mon Nov 30, 3:55PM CST
Mallinckrodt plc (MNK) announced that it has completed the previously announced divestiture of its global contrast media and delivery systems (CMDS) business to Guerbet for approximately $270 million.
MNK: 56.68 (+0.15), MYL: 45.00 (+0.12), CORT: 5.30 (-0.11)
Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
Zacks Equity Research - Zacks Investment Research - Thu Nov 26, 12:20PM CST
Roche (RHHBY) received good news when the European Commission (EC) approved its skin cancer drug Cotellic (cobimetinib) for use in combination with Zelboraf (vemurafenib).
LLY: 73.07 (+0.50), EXEL: 7.74 (+0.07)
Sanofi's Bid for Medivation Is Too Low
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 1:38PM CDT
Image source: Flickr user StockMonkeys.com. After waiting for weeks for a reply to its M&A offer, drug giant Sanofi has gone public with a $9.3 billion bid to acquire mid-cap cancer drugmaker Medivation . Sanofi's purchase price is...
MDVN: 58.89 (-0.08), JNJ: 116.46 (+0.28), GILD: 82.45 (+0.66), SNY: 40.29 (+0.50), NVS: 79.71 (+0.25)
J&J's Q1 Results Suggest More Upside for Medivation, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 7:01AM CDT
SOURCE: JOHNSON & JOHNSON Johnson & Johnson has reported its first-quarter financials, and the report shows that market share for its top selling prostate cancer drug Zytiga slipped slightly in the quarter. The loss of market share in...
MDVN: 58.89 (-0.08), JNJ: 116.46 (+0.28)
Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 10:50AM CDT
Medivation (MDVN) and Astellas (ALPMY) announced that the EMA's CHMP has issued a positive opinion in favor of the inclusion of new data in Xtandi's label.
MDVN: 58.89 (-0.08), AZN: 28.70 (+0.06), AMAG: 24.46 (+0.83)
Medivation Prostate Cancer Drug Xtandi under Pricing Attack
Arpita Dutt - Zacks Investment Research - Tue Mar 29, 9:30AM CDT
Americans are charged more for Medivation's (MDVN) prostate cancer drug, Xtandi, compared to countries like Sweden, Japan and Canada.
MDVN: 58.89 (-0.08), VRX: 21.64 (unch)
Technical Data Influencing the Market - Analyst Notes on CUBA Beverage, Arch Therapeutics, Wolseley and Astellas Pharma
ACCESSWIRE - Wed Mar 09, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CUBA Beverage Co. (OTC: CUBV), Arch Therapeutics Inc. (OTC: ARTH), Wolseley PLC (OTC: WOSYY) and Astellas Pharma Inc. (OTC: ALPMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
3 Reasons Medivation, Inc. Stock Could Rise
Cory Renauer, The Motley Fool - Motley Fool - Fri Mar 04, 2:39PM CST
Along with the rest of the healthcare industry, Medivation stock has had a rough year, even despite a 10% pop following recently-announced strong fourth-quarter earnings. The boost was especially welcome after the beating Medivation has received...
MDVN: 58.89 (-0.08), JNJ: 116.46 (+0.28)
Amgen Kyprolis' Label Expanded, Repatha Approved in Japan
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 3:30PM CST
The label for Amgen's (AMGN) Kyprolis has been expanded in the U.S. and accelerated approval has been converted to full approval; Repatha gains approval in Japan.
AMGN: 149.81 (+0.39), ANIK: 50.27 (+0.10), CELG: 99.23 (+2.37)
Where We Are Headed - Featured Research on Airbus Group, Astellas Pharma, Brambles and Detour Gold
ACCESSWIRE - Fri Jan 22, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Airbus Group SE (OTC: EADSY), Astellas Pharma Inc. (OTC: ALPMY), Brambles Ltd. (OTC: BXBLY) and Detour Gold Corp. (OTC: DRGDF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Ironwood Highlights Strategic Objectives, Provides Outlook
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 3:25PM CST
Ironwood Pharmaceuticals (IRWD) provided a comprehensive overview of its initiatives by highlighting three- and five-year operational and financial goals.
AGN: 228.55 (-3.00), IRWD: 12.64 (-0.04), AZN: 28.70 (+0.06)
Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:50PM CST
Vical's (VICL) antifungal candidate, VL-2397, was granted Orphan Drug designation for the treatment of patients with invasive aspergillosis.
VICL: 4.36 (+0.03), HZNP: 16.78 (+0.04), LGND: 113.83 (-0.16)
Ocata Therapeutics Almost Doubled in November -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Fri Dec 04, 3:03PM CST
What: Shares of eye-disease-focused Ocata Therapeutics posted a huge 88% gain during the month of November after the company accepted a buyout offer for a healthy premium, according to data from S&P Capital IQ . So what: Early in the...
OCAT: 8.47 (+0.01)
Ironwood/Astellas Report Positive Phase III Data on Linzess
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 3:55PM CST
Ironwood Pharmaceuticals (IRWD) and Astellas reported positive top-line phase III data on Linzess; Astellas will file for its approval in Japan in 2016.
AGN: 228.55 (-3.00), IRWD: 12.64 (-0.04), ACHN: 8.40 (-0.02)
Mallinckrodt (MNK) Sells Contrast Media & Delivery Systems
Zacks Equity Research - Zacks Investment Research - Mon Nov 30, 3:55PM CST
Mallinckrodt plc (MNK) announced that it has completed the previously announced divestiture of its global contrast media and delivery systems (CMDS) business to Guerbet for approximately $270 million.
MNK: 56.68 (+0.15), MYL: 45.00 (+0.12), CORT: 5.30 (-0.11)
Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
Zacks Equity Research - Zacks Investment Research - Thu Nov 26, 12:20PM CST
Roche (RHHBY) received good news when the European Commission (EC) approved its skin cancer drug Cotellic (cobimetinib) for use in combination with Zelboraf (vemurafenib).
LLY: 73.07 (+0.50), EXEL: 7.74 (+0.07)
